“The FDA’s and EMEA’s formal agreement with our clinical study design is a major accomplishment for Zelos Therapeutics and a significant regulatory milestone for the development of this important new anabolic agent for the treatment of osteoporosis,” stated Dr. Brian MacDonald, Zelos Therapeutics’ Chief Executive Officer. “We now have a clearly defined development path that could lead to the approval of ZT-031, which we believe is the most advanced development-stage osteoporosis agent in its therapeutic class. The previous 12-month Phase 2 study demonstrated that ZT-031 produces rapid, clinically meaningful increases in bone formation, creating the potential for improved outcomes for patients with severe osteoporosis.”
ZT-031, a parathyroid hormone analog, will be evaluated against alendronate (Fosamax®) in the first active comparator osteoporosis registration study. The 24-month Phase 3 study is expected to enroll 3,255 post-menopausal women with severe osteoporosis. The primary efficacy endpoint is the incidence of new vertebral fractures in the ZT-031 study arm compared with the alendronate study arm. In addition, the FDA and EMEA have agreed to an innovative weight-based dosing regimen in which different dose strengths of ZT-031 will be used in patients in different weight categories. Zelos Therapeutics believes that the safety and efficacy profile of ZT-031 that has been demonstrated to date, coupled with the anticipated improvements in clinical benefit that may result from weight-based dosing, could position ZT-031 favorably against Forteo® (teriparatide), the only bone formation therapeutic currently approved for use in the United States.
About Osteoporosis
Osteoporosis is a disease in which bones become fragile and are more likely to break. If not prevented or if left untreated, osteoporosis can progress painlessly until a bone breaks or fractures, typically in the hip, spine, and wrist. Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. The World Health Organization classifies osteoporosis as second only to cardiovascular disease in the severity of its effects. In the U.S. alone, more than 44 million men and women have osteoporosis, or low bone-mineral density. Thirty percent of women and 10 percent of men in the U.S. will develop osteoporosis during their lifetime.
About ZT-031
ZT-031 (formerly Ostabolin-C™) is a proprietary cyclic 31-amino acid parathyroid hormone (PTH) analog being developed for the treatment of osteoporosis. ZT-031 was recently studied in a 12-month double-blind, placebo-controlled Phase 2 study in 261 postmenopausal women with low bone mass (osteoporosis) at either the hip or the lumbar spine. In this study, ZT-031 was shown to be a bone formation agent with a rapid onset of effect leading to clinically relevant increases in bone mineral density (BMD) with no adverse events due to hypercalcemia observed.
About Zelos Therapeutics, Inc.
Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos Therapeutics is advancing a portfolio of product opportunities into late-stage clinical trials. For more information about Zelos Therapeutics, please visit the Company’s website at www.zelostherapeutics.com.
Fosamax® is a registered trademark of Merck & Co., Inc.
Forteo® is a registered trademark of Eli Lilly and Company
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are forward-looking statements are based upon current expectations and assumptions that are subject to numerous risks and uncertainties. Our actual results may differ materially from those contained in such forward-looking statements.
Contact:
Investor Contact Zelos Therapeutics, Inc. Alan Roemer, 610-825-1468 Chief Financial Officer or Media Contact MacDougall Biomedical Communications Douglas MacDougall, 781-235-3060
Source: Zelos Therapeutics, Inc.
